These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 25122038)

  • 1. Hippocampal volume and the rapid antidepressant effect of ketamine.
    Abdallah CG; Salas R; Jackowski A; Baldwin P; Sato JR; Mathew SJ
    J Psychopharmacol; 2015 May; 29(5):591-5. PubMed ID: 25122038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antidepressant efficacy of subanesthetic-dose ketamine does not correlate with baseline subcortical volumes in a replication sample with major depressive disorder.
    Niciu MJ; Iadarola ND; Banerjee D; Luckenbaugh DA; Park M; Lener M; Park L; Ionescu DF; Ballard ED; Brutsche NE; Akula N; McMahon FJ; Machado-Vieira R; Nugent AC; Zarate CA
    J Psychopharmacol; 2017 Dec; 31(12):1570-1577. PubMed ID: 29039254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
    Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
    Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder.
    Zhou YL; Wu FC; Wang CY; Zheng W; Lan XF; Deng XR; Ning YP
    J Affect Disord; 2020 Nov; 276():608-615. PubMed ID: 32871692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression.
    Siegel JS; Palanca BJA; Ances BM; Kharasch ED; Schweiger JA; Yingling MD; Snyder AZ; Nicol GE; Lenze EJ; Farber NB
    Psychopharmacology (Berl); 2021 Apr; 238(4):1157-1169. PubMed ID: 33483802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial.
    Murrough JW; Iosifescu DV; Chang LC; Al Jurdi RK; Green CE; Perez AM; Iqbal S; Pillemer S; Foulkes A; Shah A; Charney DS; Mathew SJ
    Am J Psychiatry; 2013 Oct; 170(10):1134-42. PubMed ID: 23982301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.
    Park L; Furey M; Nugent AC; Farmer C; Ellis J; Szczepanik J; Lener MS; Zarate CA
    Int J Neuropsychopharmacol; 2019 Jan; 22(1):10-18. PubMed ID: 30184133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.
    Dwyer JB; Landeros-Weisenberger A; Johnson JA; Londono Tobon A; Flores JM; Nasir M; Couloures K; Sanacora G; Bloch MH
    Am J Psychiatry; 2021 Apr; 178(4):352-362. PubMed ID: 33653121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disentangling the association of depression on the anti-fatigue effects of ketamine.
    Saligan LN; Farmer C; Ballard ED; Kadriu B; Zarate CA
    J Affect Disord; 2019 Feb; 244():42-45. PubMed ID: 30312839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
    Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
    J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine.
    Lally N; Nugent AC; Luckenbaugh DA; Niciu MJ; Roiser JP; Zarate CA
    J Psychopharmacol; 2015 May; 29(5):596-607. PubMed ID: 25691504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder.
    Aust S; Gärtner M; Basso L; Otte C; Wingenfeld K; Chae WR; Heuser-Collier I; Regen F; Cosma NC; van Hall F; Grimm S; Bajbouj M
    Eur Neuropsychopharmacol; 2019 Apr; 29(4):529-538. PubMed ID: 30772118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression.
    Cornwell BR; Salvadore G; Furey M; Marquardt CA; Brutsche NE; Grillon C; Zarate CA
    Biol Psychiatry; 2012 Oct; 72(7):555-61. PubMed ID: 22521148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hippocampal volume predicts antidepressant efficacy in depressed patients without incomplete hippocampal inversion.
    Colle R; Cury C; Chupin M; Deflesselle E; Hardy P; Nasser G; Falissard B; Ducreux D; Colliot O; Corruble E
    Neuroimage Clin; 2016; 12():949-955. PubMed ID: 27995060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of ketamine on circadian rhythm and synaptic homeostasis in patients with treatment-resistant depression: A protocol for mechanistic studies of its rapid and sustained antidepressant actions in humans.
    Zhuo C; Tian H; Li G; Chen M; Jiang D; Lin X; Xu Y; Wang W
    Brain Behav; 2019 Nov; 9(11):e01423. PubMed ID: 31617335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
    Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
    Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
    Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
    J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Right dorsolateral prefrontal cortex volumetric reduction is associated with antidepressant effect of low-dose ketamine infusion: A randomized, double-blind, midazolam-controlled PET-MRI clinical trial.
    Li WC; Chen LF; Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Tu PC; Chen MH
    J Affect Disord; 2023 Aug; 335():105-110. PubMed ID: 37178823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.